KRAS Mutation — the most frequently mutated oncogene in human cancer was 'undruggable' for 40 years until sotorasib broke through. KRAS G12C inhibitors are now FDA-approved for lung cancer, with G12D inhibitors in clinical trials.
Whole genome sequencing evaluates all KRAS codon 12, 13, and 61 variants — G12C, G12D, G12V, G13D, Q61H — providing comprehensive KRAS profiling for targeted therapy eligibility across lung, colorectal, and pancreatic cancers.
KRAS Mutation
KRAS (Kirsten rat sarcoma viral oncogene homolog, chromosome 12p12.1) is the most frequently mutated oncogene in human cancer — found in approximately 25% of all cancers, including ~30-40% of NSCLC (adenocarcinoma), ~40-50% of colorectal cancer, and ~90% of pancreatic cancer. KRAS mutations constitutively activate the RAS-RAF-MEK-ERK signaling pathway, driving cell proliferation. For four decades, KRAS was considered 'undruggable' due to the protein's smooth surface lacking a druggable binding pocket.
Sotorasib (Lumakras, FDA 2021) was the first drug to successfully target KRAS — specifically the G12C mutation (glycine to cysteine at position 12). Sotorasib exploits the unique cysteine at position 12 to covalently and irreversibly bind KRAS G12C in its inactive GDP-bound state, locking the protein off. KRAS G12C is found in approximately 13% of NSCLC (adenocarcinoma), 3% of CRC, and 1-2% of other cancers. Adagrasib (Krazati) is a second FDA-approved KRAS G12C inhibitor with longer half-life and CNS penetration.
The KRAS revolution is expanding beyond G12C. KRAS G12D inhibitors (MRTX1133 and others) are in clinical trials — critically important because G12D is the most common KRAS mutation across all cancers (representing ~36% of KRAS-mutant pancreatic cancer). G12V and other codon inhibitors are in preclinical development. Additionally, KRAS mutation status determines anti-EGFR antibody eligibility in CRC — KRAS-mutant CRC does NOT respond to cetuximab or panitumumab, making KRAS testing mandatory before anti-EGFR therapy.
KRAS-mutant CRC does NOT respond to anti-EGFR antibodies (cetuximab, panitumumab) — testing is MANDATORY before prescribing. Giving anti-EGFR therapy to a KRAS-mutant patient wastes time and money while delaying effective treatment.
KRAS testing determines targeted therapy eligibility (sotorasib/adagrasib for G12C), anti-EGFR antibody exclusion (all KRAS mutations in CRC), and clinical trial access (G12D inhibitors). WGS identifies all KRAS variants comprehensively.
KRAS G12D inhibitors are in clinical trials — the most important codon for pancreatic cancer treatment
KRAS G12D is the most common KRAS mutation in pancreatic cancer (~36%) and is found in ~9% of NSCLC and ~12% of CRC. MRTX1133 and other G12D-specific inhibitors are in early clinical trials. Establishing KRAS G12D status now — through WGS — enables rapid trial enrollment as these therapies advance through development. For pancreatic cancer patients with limited treatment options, clinical trial access can be life-extending.
Sotorasib and adagrasib produce responses in previously untreatable KRAS-mutant NSCLC — molecular testing identifies eligible patients
KRAS G12C NSCLC was previously treated with standard chemotherapy and immunotherapy without a targeted option. Sotorasib produces ~37% response rate and adagrasib ~43% in previously treated KRAS G12C NSCLC — meaningful responses in a patient population that has exhausted standard therapies. Without KRAS molecular testing, these patients never receive the targeted therapy they're eligible for.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for KRAS Mutation and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
